Introduction {#Sec1}
============

Adalimumab, a fully human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, was approved for the treatment of rheumatoid arthritis (RA) in April 2008 in Japan with the data of the CHANGE study and an overseas clinical trial \[[@CR1], [@CR2]\]. The key findings that led to its initial approval were significantly improved American College of Rheumatology (ACR) outcomes achieved with adalimumab compared with placebo in patients with RA previously failing treatment with at least one disease-modifying antirheumatic drug (DMARD). Therefore, the initial approval for adalimumab was limited to use in patients who had inadequately responded to DMARDs (established patients), and a request was made to conduct a postmarketing observational study (PMOS) involving established and DMARD and biologic treatment-naïve patients with RA to obtain sufficient safety and effectiveness data on adalimumab to optimize its use in RA in clinical practice.

A double-blind, placebo-controlled study was also conducted to evaluate the preventive effect on progressive joint destruction in Japanese patients with RA (HOPEFUL-1 study) \[[@CR3]\]. Based on the results of the HOPEFUL-1 study, the Japanese regulatory authority \[Pharmaceuticals and Medical Devices Agency (PMDA)\] approved an additional indication for adalimumab for the prevention of structural joint damage in patients with RA. This approval offered DMARD-naïve patients at risk of early structural joint damage a chance to receive adalimumab as a first-line treatment for RA. We designed the present PMOS to examine the real-world safety profile and effectiveness of adalimumab plus methotrexate (MTX) for the treatment of patients with RA.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This multicenter prospective PMOS was conducted between February 2013 and April 2015 at 84 centers in Japan. The primary objective was to examine the safety profile of adalimumab in daily clinical practice of patients with RA showing rapid progression of structural damage of the joints who have no prior history of treatment with DMARDs or biologic agents. The safety profile of adalimumab was compared between DMARD-naïve patients and established patients (*n* = 7740) included and analyzed in the completed all-case PMOS \[[@CR4]\]. The secondary objective was to establish the real-world effectiveness of adalimumab plus MTX on disease activity as assessed using Disease Activity Score based on the 28-joint count (DAS28), Clinical Disease Activity Index (CDAI), and Simplified Disease Activity Index (SDAI) in DMARD- and biologic-naïve patients with RA showing rapid progression of structural joint damage. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

Subjects {#Sec4}
--------

The sample size was based on the adverse event (AE) profile of a previous PMOS in Japanese patients with RA treated with adalimumab \[[@CR4]\]. The study reported that the most frequent serious AEs (SAEs) were "infections and infestations," which occurred at an incidence rate of 2.4% in patients with RA showing inadequate response to existing therapies. In a subcohort of 4129 patients receiving concomitant adalimumab and MTX, the incidence of the SAE "infections and infestations" was 2.15% (90/4129). This incidence rate was used for setting the 150-patient sample size for this study, considering that the number of patients needed for the detection of at least one patient with a serious "infection and infestation" at a statistical power of 95% was calculated to be 138. Numeric data were presented as the number of non-missing values, means, standard deviations (SDs), minimum, median, and maximum. Japanese RA patients meeting all of the following requirements were enrolled in this study: High disease activity, poor prognostic factors \[e.g., rheumatoid factor-positive, anti-cyclic citrullinated peptide (CCP) antibody-positive, and radiographic evidence of bone erosion\], indication for the combination of adalimumab and MTX, and no prior history of treatment with DMARDs and biologic agents. Patients with known contraindications to adalimumab were excluded from the analysis \[[@CR5]\].

Treatment {#Sec5}
---------

Eligible patients initiated treatment with combination adalimumab and MTX (≤16 mg/week) and were followed for 24 weeks or until early discontinuation of adalimumab. Adalimumab was prescribed by the physician in accordance with the approved label for use in patients with RA. MTX administration was started either on the same day of adalimumab administration or the next day of adalimumab administration.

Safety {#Sec6}
------

AEs were recorded up to week 28 and were coded according to the *Medical Dictionary for Regulatory Activities* (version 18.1) system organ class and preferred term. All AEs, including abnormal laboratory findings, regardless of their causal relationships to adalimumab treatment, were documented during the study period or until discontinuation of adalimumab. Each AE was described in terms of the date of its onset, seriousness, causal relationship to adalimumab, progress, treatment provided, outcome, and laboratory findings.

Measurements {#Sec7}
------------

Patients underwent baseline assessments, including evaluation of prior treatments and concomitant drug or nondrug treatments. Efficacy was measured by changes in DAS28 with erythrocyte sedimentation rate (ESR; DAS28-4ESR) and C-reactive protein (CRP; DAS28-4CRP), CDAI (morning stiffness, tender and swollen joints, and global disease activity; remission ≤2.8), and SDAI (CDAI assessment along with CRP; remission ≤3.3) \[[@CR6]\], at 0, 4, 12, and 24 weeks or at discontinuation of adalimumab before 24 weeks. Thereafter, patients were grouped into those receiving low-dose (\<8 mg/week) or high-dose (≥8 mg to ≤16 mg/week) MTX at baseline and at week 24. Subsequently, DAS28-4CRP response was evaluated in the low-dose and high-dose MTX groups at week 24. The DAS28-4CRP response based on disease duration (\<3, ≥3 to \<6, ≥6 to \<12, ≥12 to \<24, and ≥24 months) was also assessed at week 24. All data from the study were recorded in a case report form.

Statistical Analyses {#Sec8}
--------------------

Categorical data were described by number and percentage of patients in each category. Change in the proportion of patients with a DAS28-4CRP from ≥3.2 at baseline to \<3.2 at week 24 was evaluated using the McNemar test. Change in DAS28 over 24 weeks was assessed using a paired *t* test. Multivariate logistic regression analysis was used to identify demographic and baseline variables that could significantly affect the risk of AEs related to adalimumab plus MTX or the response to combination therapy. The odds ratio (OR) and its two-sided Wald 95% confidence interval (CI) were estimated for each covariate. The goodness of fit of the regression model to data was assessed using the Hosmer-Lemeshow goodness-of-fit test. To help select potential covariates to be included in the model, a univariate logistic regression analysis was performed using the safety analysis set and its multivariate logistic regression subset, and Spearman's rank correlation was used to assess the subset between each covariate and the risk of adverse drug reactions (ADRs). One of two well-correlated (Spearman's rank correlation coefficient \[*r*\] \> 0.8) variables was excluded from the model. Inferential statistics were performed at a nominal significance level of 0.05 (two-sided).

Results {#Sec9}
=======

Patient Demographics and Baseline Characteristics {#Sec10}
-------------------------------------------------

A total of 163 patients were enrolled, of whom 157 were included in the safety cohort. Patients with available DAS28 data were included in the effectiveness cohorts (Fig. [1](#Fig1){ref-type="fig"}). The mean (SD) age of the safety cohort was 56.5 (13.9) years, and most patients were women (65.6%); 73.2% and 66.9% of patients were rheumatoid factor-positive and anti-CCP antibody--positive, respectively. The mean (SD) duration of RA was 9.5 (34.4) months, and 40.8% of patients had a DAS28-4CRP score of \>5.1. Bone erosions were present in approximately 81 patients, while other reasons for arthrosis damage were present in 45 patients. Thirty-seven patients had a history of treatment with adrenal corticosteroids, whereas 51 patients had received concomitant treatment with adrenal corticosteroids. Fourteen patients received concomitant DMARDs other than MTX (Table [1](#Tab1){ref-type="table"}).Fig. 1Patient flow chart. *CDAI* Clinical Disease Activity Index, *DAS28-4ESR/-4CRP* Disease Activity Score based on 28-joint count and using erythrocyte sedimentation rate/C-reactive protein, *DMARD* disease-modifying antirheumatic drug, *SDAI* Simplified Disease Activity Index Table 1Patient demographics and baseline characteristicsDemographics and baseline characteristicsSafety cohortNo. of patients157Male/female, %34.4/65.6Age, mean (SD), years56.5 (13.9)Weight, mean (SD), kg57.77 (13.02)Duration of RA, mean (SD), months9.5 (34.4)Duration of smoking (ex-smokers), mean (SD), years20.1 (14.5)Duration of smoking (current smokers), mean (SD), years35.7 (8.9)HBs antigen test, mean (SD) Positive0 Negative153 (99.4) Unspecified1 (0.6) Not conducted3 (1.9)HBs antibody test, mean (SD) Positive14 (10.1) Negative124 (89.9) Not conducted19 (12.1)HBc antibody test, mean (SD) Positive15 (10.6) Negative126 (89.4) Not conducted16 (10.2)β-[d]{.smallcaps}-glucan in the blood, mean (SD) Positive2 (1.4) Negative137 (98.6) Not conducted18 (11.5)Peripheral white blood cell count, mean (SD), /mm^3^ ≥4000152 (97.4) \<40004 (2.6) Not conducted1 (0.6)Peripheral blood lymphocyte count, mean (SD), /mm^3^ ≥1000141 (91.6) \<100013 (8.4) Not conducted3 (1.9)Baseline DAS28-4CRP score, mean (SD) ≤5.178 (49.7) \>5.164 (40.8)Rheumatoid factor, positive, IU/ml115 (73.2)Anti-CCP antibody, positive, U/ml105 (66.9)Bone erosions, present, mean (SD)81 (51.6)Other reasons for faster arthrosis damage, present, mean (SD)45 (28.7)Comorbidities, yes, *n* (%)80 (51.0) Cardiovascular28 (35.0) Respiratory15 (18.8) Hematologic5 (6.3) Hepatic15 (18.8) Renal1 (1.3) Diabetes11 (13.8) Malignancy0 Others52 (65.0)Prior morbidities, yes, *n* (%)47 (29.9)History of allergies, yes, *n* (%)16 (10.2)Steinbrocker's stage, % I51.0 II36.3 III9.6 IV3.2Steinbrocker's class, % 135 245.9 317.2 41.9MTX initial dose, *n* (%) \<8 mg/week81 (51.6) ≥8 mg/week76 (48.4)MTX dose classification, *n* (%) High dose at baseline, high dose at week 2463 (40.1) High dose at baseline, low dose at week 242 (1.3) Low dose at baseline, high dose at week 2443 (27.4) Low dose at baseline, low dose at week 2429 (18.5) Other than the above mentioned20 (12.7)Prior use of corticosteroids, yes, *n* (%)37 (23.6)Concomitant use of corticosteroids, yes, *n* (%)51 (32.5)Concomitant use of DMARDs other than MTX, yes, *n* (%)14 (8.9)*CCP* cyclic citrullinated peptide, *DAS28-4CRP* Disease Activity Score based on 28-joint count and using C-reactive protein, *DMARD* disease-modifying antirheumatic drug; *HBc* hepatitis B core, *HBs*, hepatitis B surface, *MTX* methotrexate, *RA* rheumatoid arthritis, *SD* standard deviation

Change in MTX Dosage at Week 24 {#Sec11}
-------------------------------

Of the patients enrolled, 142 were receiving MTX at baseline. A greater proportion of patients on low-dose MTX (≤8 mg/week MTX; 44/74) escalated to high-dose MTX (\>8 mg/week) at week 24, while 30 patients continued to receive low-dose MTX. A greater majority of patients who entered the study on high-dose MTX (66/68) continued to receive high-dose MTX; 2 patients switched to low-dose MTX. In the safety cohort (*n* = 157), MTX was discontinued at week 24 in 19 patients due to insufficient effect (*n* = 3 \[15.8%\]), AEs (*n* = 5 \[26.3%\]), and other reasons (*n* = 11 \[57.9%\]).

Safety {#Sec12}
------

To examine the safety profile of adalimumab in combination with MTX in clinical practice in DMARD- and biologic-naïve patients at risk of early structural joint damage, we analyzed AE data obtained from the 157 patients included in the safety analysis set. A total of 37 ADRs occurred in 29 patients (18.47%; Table [2](#Tab2){ref-type="table"}). The most common ADRs were "infections and infestations" (*n* = 7; 4.46%) and "general disorders and administration site conditions" (*n* = 4; 2.55%).Table 2Adverse drug reaction profile based on MTX doseMTX dosage groups at baselineTotalTotalHigh dose (≥8 mg/week)Low dose (\<8 mg/week)MTX dosage groups at week 24*n* = 157High dose *n* = 66Low dose *n* = 2High dose *n* = 43Low dose *n* = 30Non-seriousSeriousNon-seriousSeriousNon-seriousSeriousNon-seriousSeriousNon-seriousSeriousNo. of ADR onset cases2542970209121No. of ADRs32537902013231Incidence of ADRs, %16.32.618.511.10100020.92.36.93.4Infectious and parasitic diseases72920002001 Gastroenteritis10110000000 Nasopharyngitis20210001000 Pyelonephritis01100000001 Herpes zoster10100001000 Pulpitis dental10100000000 Pneumonia10100000000 Pneumonia bacterial10100000000 *Pneumocystis jiroveci* pneumonia01100000000Immune system disorders10100000000 Hypersensitivity10100000000Psychiatric disorder10100001000 Dysphoria10100001000Cardiac disorder01100000100 Pericarditis01100000100Respiratory, thoracic and mediastinal disorders02200000100 Interstitial lung disease01100000000 Pleurisy01100000100Skin and subcutaneous tissue disorders20200002000 Alopecia00000000000 Pruritus10100001000 Rash10100001000Musculoskeletal and connective tissue disorder10100001000 Arthralgia10100001000Gastrointestinal disorder10110000000 Nausea10110000000General disorders and administration site conditions40410001010 Injection site reaction10110000000 Chills10100001000 Pyrexia10100001000 Injection site erythema10100000010 Peripheral edema10100000000 Event that cannot be evaluated10100001000 Laboratory tests1001040203010 Increase in alanine aminotransferase20210001000 Increase in aspartate aminotransferase20210001000 Decrease in white blood cell count20210000010Abnormal liver function test30300200000 Elevation of liver enzyme10110000000 Abnormal liver enzymes10110001000 Increase in β-[d]{.smallcaps}-glucan in the blood10100001000 Decrease in blood platelet count10100000010*ADR* adverse drug reaction, *MTX* methotrexate

Multivariate logistic regression analysis of the incidence of ADRs was performed to identify demographic or baseline variables influencing the safety of adalimumab plus MTX (data not shown). All potential covariates included in the regression model had an OR for which the two-sided Wald 95% CI was wide and crossed 1. Therefore, there was no clear indication for the direction of their association with the risk of ADRs during combination therapy. There were five SAEs in four patients (2.55%) \>60 years of age. The SAEs included pyelonephritis, *Pneumocystis jiroveci* pneumonia, interstitial lung disease, and pleurisy. The outcomes of these patients from these SAEs were either recovered or recovering. Pericarditis was the only unexpected event according to the current Japanese label. The patient was a 62-year-old female, without a history or comorbidities of cardiovascular disease, who had initiated treatment with adalimumab in June 2013. The patient was diagnosed with acute pericarditis 4 months after the start of treatment; adalimumab was discontinued 5 months after administration. Pericarditis resolved by 8 months after administration; however, miliary tuberculosis was then diagnosed in this patient and she died. According to the treating physician, the diagnosis of miliary tuberculosis was not considered related to treatment.

The incidence of ADRs was also analyzed by MTX dosage at baseline and week 24. Twenty patients were excluded from the safety data set because of missing data at these time points. The patients treated with ≥8 mg/week MTX at baseline experienced no serious ADRs. Two of the patients treated with \<8 mg/week MTX at baseline experienced serious ADRs; one patient treated with \<8 mg/week MTX at baseline and ≥8 mg/week MTX at week 24 experienced pericarditis and pleurisy and one patient treated with \<8 mg/week MTX at both baseline and week 24 experienced pyelonephritis. There was no numerical difference in the incidence of ADRs between MTX dosage at baseline and week 24.

DAS28-4CRP Response at 24 Weeks Based on Disease Duration {#Sec13}
---------------------------------------------------------

Nearly all of the patients in the DAS28-4CRP effectiveness cohort (134/140 \[95.7%\]) had disease duration \<2 years; of these patients, approximately ≥80% had moderate or high disease activity (DAS28-4CRP ≥3.2) at baseline. After 24 weeks of treatment, approximately ≥50% patients achieved remission or low disease activity (DAS28-4CRP \<3.2). In comparison, only two of six patients (33.3%) with RA ≥2 years duration achieved remission or low disease activity (DAS28-4CRP \<3.2) at week 24 (Table [3](#Tab3){ref-type="table"}).Table 3DAS28-4CRP response at 24 weeks based on disease duration (*n* = 140)Duration of RA (months)*n*DAS28-4CRP at baselineDAS28-4CRP at week 24McNemar's test^b^\<3.2≥3.2\<3.2≥3.2*n*%^a^*n*%^a^*n*%^a^*n*%^a^*nP* value\<355610.94683.63258.211.833\<0.0001≥3 to \<65311.94686.82852.859.429\<0.0001≥6 to \<1220315.01680.01155.000.0----≥12 to \<24600.06100.0350.0233.3----≥24600.06100.0233.300.0----*DAS28-4CRP* Disease Activity Score based on 28-joint count and using C-reactive protein, *RA* rheumatoid arthritis^a^The denominator of the ratio is the number of target cases of each RA disease activity classification^b^McNemar's test evaluated the change in proportion of patients with DAS28-4CRP ≥3.2 at baseline to \<3.2 at week 24; analysis could not be performed because of missing data in patients with a disease duration ≥6 months

A significant proportion of patients with disease duration \<6 months (\<3 months and from ≥3 to \<6 months) had a decrease in DAS28-4CRP from ≥3.2 to \<3.2 at week 24 (McNemar's test; *P* \< 0.0001) compared with baseline. Because of the small number of patients, the DAS28-4CRP response at 24 weeks could not be evaluated statistically in patients with disease duration ≥6 months (Table [3](#Tab3){ref-type="table"}).

DAS28-4CRP Response at 24 Weeks Based on MTX Dose {#Sec14}
-------------------------------------------------

DAS28-4CRP remission (\<2.6) was achieved in patients in both the low-dose and high-dose MTX groups at week 24 (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2DAS28-4CRP response at 24 weeks based on MTX dose (*n* = 131). *DAS28-4CRP* Disease Activity Score based on 28-joint count and using C-reactive protein, *MTX* methotrexate, *SD* standard deviation

Efficacy Based on Change in Disease Activity {#Sec15}
--------------------------------------------

There was a significant improvement/reduction in disease activity over 24 weeks assessed by change in DAS28-4ESR, DAS28-4CRP, SDAI, and CDAI scores from 5.61, 5.01, 32.30, and 29.18 at baseline to 2.41, 1.92, 4.58, and 3.96 at week 24, respectively (*P* \< 0.05). A steep decline in disease activity was seen as early as week 4, and this improvement in disease activity was sustained for 24 weeks (Fig. [3](#Fig3){ref-type="fig"}). Overall, 37 patients (23.6%) from the safety cohort discontinued adalimumab before week 24 because of insufficient effect (*n* = 12), AEs (*n* = 7), lost to follow-up (*n* = 6), remission (*n* = 4), financial reasons (*n* = 3), patient preference (*n* = 2), change in hospital (*n* = 1), and other reasons (*n* = 2). Multivariate regression analysis showed that baseline patient characteristics such as cardiac disorder (OR, 4.1; 95% CI, 0.9--18.5), blood disorder (OR, 2.9; 95% CI, 0.1--83.5), history of drug allergy (OR, 1.6; 95% CI, 0.1--25.2), peripheral white blood cell count ≥4000/mm^3^ (OR, 6.5; 95% CI, 0.2--193.3), and concomitant use of adrenal corticosteroids (OR, 1.8; 95% CI, 0.7--4.8) are likely to negatively impact remission (Table S1). Similarly, univariate regression analysis showed that baseline patient characteristics such as age ≥65 years (OR, 1.6; 95% CI, 0.8--3.5), weight ≥50 to \<60 kg (OR, 1.8; 95% CI, 0.6--5.2), peripheral blood lymphocyte count ≥1000/mm^3^ (OR, 1.6; 95% CI, 0.5--5.4), and concomitant use of adrenal corticosteroids (OR, 1.6; 95% CI, 0.7--3.4) are likely to negatively impact remission (Table S2).Fig. 3Change in DAS as assessed using **a** DAS28-4ESR, **b** DAS28-4CRP, **c** SDAI, and **d** CDAI scores. *CDAI* Clinical Disease Activity Index, *DAS28-4ESR/-4CRP* Disease Activity Score based on 28-joint count and using erythrocyte sedimentation rate/C-reactive protein, *SDAI* Simplified Disease Activity Index. \*Paired *t* test

Discussion {#Sec16}
==========

This study provides the first prospective real-world evidence from routine clinical practice of combination therapy initiated in DMARD and biologic treatment-naïve patients with RA at risk of progressive joint damage. Results indicate that treatment with adalimumab in combination with MTX is safe and effective.

Of the 157 patients evaluated for safety, 29 patients (18.47%) experienced an ADR. The most common ADRs in this study were "infections and infestations" (*n* = 9; 5.73%) and "general disorders and administration site conditions" (*n* = 4; 2.55%). There was one case of pericarditis; however, this case resolved and was not considered to be related to treatment. In the postmarketing surveillance of 7740 established patients with RA, the incidence of ADRs was 24%; the most common ADRs were "skin and subcutaneous disorders" (7.2%), followed by "infections and infestations" (7.0%) \[[@CR4]\]. Thus, these results indicate that no particular ADR was observed in the present study in contrast to the previous case study \[[@CR4]\]. There was no apparent relationship between the incidence of ADRs and the MTX dose. Four SAEs were reported in this study: pyelonephritis, *Pneumocystis jiroveci* pneumonia, interstitial lung disease, and pleurisy occurred in one patient each, and pericarditis of unknown severity occurred in one patient. Although the outcomes of all SAEs were either recovered or recovering (including the case of pericarditis), the causal relationship between adalimumab and pericarditis cannot be ruled out, as the event developed after adalimumab administration. Overall, the ADR profile and frequency in DMARD- and biologic-naïve RA patients at risk of progressive joint damage were similar to those previously reported in patients with established RA, suggesting that the early intensive therapy with adalimumab did not adversely affect the existing safety profile.

There were 37 patients who discontinued the combination treatment with adalimumab and MTX before week 24, of which 12 patients discontinued because of insufficient effect. This suggests that there were TNF-alpha non-responders even among patients who had no prior history of exposure to DMARDs and biologics. Therefore, physicians should select appropriate treatment options besides TNF-alpha inhibitors on the basis of careful observation and accurate diagnosis.

Of note, approximately ≥50% of patients achieved remission or low disease activity (DAS28-4CRP response) at week 24. This patient population included 95.5% of patients with a disease duration \<2 years and ≥80% of patients with moderate or high disease activity at baseline. These results were consistent with previous reports of clinical trials with the combination therapy \[[@CR3], [@CR7]\]. In both Japanese and international clinical trials, poor prognostic factors (rheumatoid factor-positive, anti-CCP antibody--positive, or bone erosion) were features observed in patients with a disease duration of \<2 years. ACR guidelines recommend the use of anti-TNF inhibitors with or without MTX in patients with disease duration of \<6 months with high disease activity and features of poor prognosis \[[@CR8]\]. Eventually, the intensive use of biologics for the patients in this study was deemed to be reasonable.

Japanese studies have evaluated the clinical effectiveness of adalimumab in combination with higher doses of MTX (\>8 mg/week) using both small \[[@CR9], [@CR10]\] and large sample sizes \[[@CR4], [@CR11]\]. In the present study, we observed DAS28-4CRP remission (\<2.6) in most patients at week 24 regardless of the MTX dose. The real-world observational nature of the study indicates that a dose of MTX based on the patient's background, condition, and response to the therapies, as assessed by the treating physician, would be beneficial for patients. The present results are consistent with a post hoc analysis of the MELODY study, which suggested that 8 mg/week of MTX should be an adequate dose for biologic-naïve patients \[[@CR11]\], and the HOPEFUL-1 study, which indicated that adalimumab with MTX is safe and efficacious in suppressing disease progression (with radiographic assessments) and improving clinical outcomes in Japanese patients with disease duration of \<2 years and high disease activity \[[@CR3]\]. A similar response was seen in Western patients with RA, in whom increasing doses of MTX in combination with adalimumab showed a statistically significant trend toward improved clinical outcomes; however, in patients with disease duration of \<1 year, the efficacy of MTX at 10- and 20-mg/week was equivalent \[[@CR12]\]. Both univariate and multivariate regression analysis in the present study also indicated that the dose of MTX is not likely to affect remission. However, baseline patient characteristics, such as cardiac disorder, blood disorder, history of drug allergy, peripheral white blood cell count ≥4000/mm^3^, concomitant use of adrenal corticosteroids, age ≥65 years, weight ≥50 to \<60 kg, and peripheral blood lymphocyte count ≥1000/mm^3^, were likely to have a negative impact on remission.

We observed a steep decline in disease activity as early as week 4, and this improvement was sustained for 24 weeks. All disease activity scores (DAS28-4ESR, DAS28-4CRP, SDAI, and CDAI) showed significant improvement approaching remission at week 24. This improvement in disease activity was similar to that reported in the HOPEFUL-1 study \[[@CR7]\], indicating that the combination of adalimumab and MTX was equally effective in reducing disease activity in the real-world scenario. The results suggest that in patients with disease duration of \<2 years with high disease activity and anticipated progressive joint damage, the MTX dose used in combination with adalimumab was appropriately assessed in routine clinical practice.

Although direct comparisons cannot be made, the decline in disease activity is consistent with results from adalimumab and MTX combination therapy used in randomized controlled trials conducted in Japan \[[@CR3], [@CR7]\] and in the West in the treatment with DMARDs, MTX, and/or biologic-naïve patient populations with early RA \[[@CR12]--[@CR16]\]. Although not evident from this study, adalimumab and MTX combination therapy could contribute to inhibit bone erosion \[[@CR17]\]. Therefore, early adalimumab treatment with MTX is expected to improve clinical function in patients with high disease activity and can be considered effective in this patient population.

Study limitations included the open-label, observational study design, which reflects real-world practice. There was no restriction on the treatment or the use of concomitant medications. There were limitations for obtaining the data, leading to missing data at some specified time points. As this was a mandatory postmarketing study requested by the PMDA, we did not include the radiological examination, influence of quality of life and cost benefit evaluation. In addition, the collection of effectiveness data for this study might have been limited by the perceived clinical need for collecting data for the care of the patient in routine clinical practice.

Conclusions {#Sec17}
===========

This PMOS is the first to examine the real-world safety and effectiveness of adalimumab and MTX in DMARD- and biologic-naïve Japanese patients with RA at risk of progressive structural joint damage. The results from the study raised no new concerns about the safety of adalimumab with MTX therapy and confirmed the previous findings that combination therapy significantly decreased disease activity assessed using various measures and helped achieve clinical remission. This study suggests that adalimumab in combination with MTX could be a beneficial treatment option for this patient population.
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